A pro-regenerative cell discovered by researchers at Ohio State and the University of Michigan could open the door to potentially groundbreaking immunotherapeutic treatments for diseases such as ALS and multiple sclerosis.
BioSpace Global Roundup, March 26
Antibodies, Business, Clinical Trials, Consortium, Coronavirus Disease (COVID-19) Pandemic, European Medicines Agency (EMA), European Patent Office, FDA/Regulatory, Immuno-oncology, Immunotherapeutics, Messenger RNA (mRNA) Vaccines, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Peptides, R&D, Vaccines, X-raysA recap of business developments from life sciences companies around the world, including U.K.-based Vaccitech Limited and the University of Oxford touting positive safety and efficacy trends in a mid-stage prostate cancer study.
AbbVie Inc., along with Teneobio Inc. and that company’s affiliate TeneoOne Inc., announced that they have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.
Boehringer Ingelheim exercised an option to buy an EMBL Ventures portfolio company, ViraTherapeutics.